Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Are Thin, Early-Stage Nodular Melanomas Really Low-Risk?

Source: Cancer Network, June 2019 Even thin T1 nodular primary melanomas are associated with “a constellation of aggressive characteristics” that might worsen patient prognosis compared with superficial spreading melanoma, according to findings from an international study published in the Journal of the National Cancer Institute. The findings challenge longstanding assumptions about the life-threatening aggressiveness of nodular melanomas. Nodular […]

Report Reveals Immunotherapy is the Most Prominent Topic in Melanoma Research Globally

Source: Targeted Oncology, June 2019 Approximately one-third to one-half of patients with advanced melanoma respond to PD-1 inhibitor therapy, which is superior to response rates observed with systemic chemotherapy or even single-agent ipilimumab (Yervoy)—a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocker and the first checkpoint inhibitor approved for melanoma.1-4Nevertheless, a significant proportion of patients have primary, or […]

Posted in Melanoma News, Patients, Latest News

Dr. Daud Discusses the Immunogenicity of Melanoma

Source: OncLive, June 2019 Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma. Melanoma stands out compared with other solid tumors in terms of its immunogenicity, Daud says. For years, patients with melanoma were treated with […]

Melanoma Investigators Strive to Overcome PD-1 Inhibitor Resistance

Source: Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma. Melanoma stands out compared with other solid tumors in terms of its immunogenicity, Daud says. For years, patients with melanoma were treated with interleukin-2 and interferon […]